Call for emergency action to limit global temperature increases, restore biodiversity and protect health (5 September, 2021)

Journal of Epidemiology & Community Health
December 2021 – Volume 75 – 12
https://jech.bmj.com/content/75/12

 

Editorial
Call for emergency action to limit global temperature increases, restore biodiversity and protect health (5 September, 2021)
Lukoye Atwoli, Abdullah H Baqui, Thomas Benfield, Raffaella Bosurgi, Fiona Godlee, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Carlos Augusto Monteiro, Ian Norman, Kirsten Patrick, Nigel Praities, Marcel GM Olde Rikkert, Eric J Rubin, Peush Sahni, Richard Smith, Nicholas J Talley, Sue Turale, Damián Vázquez

COVID-19: where do we go from here?

The Lancet
Dec 18, 2021 Volume 398 Number 10318 p2207-2306
https://www.thelancet.com/journals/lancet/issue/current

 

Editorial
COVID-19: where do we go from here?
The Lancet
The end of 2021 brings a sense of uncertainty. Parts of the world are approaching a transition or a new phase of the COVID-19 pandemic. The window for pursuing the elimination of SARS-CoV-2 has closed. Moving towards a so-called post-pandemic world will be far more complicated than scenarios such as “Zero COVID”. The challenge now is to determine the level of COVID-19 that is acceptable for individual nations in a fundamentally interconnected world. In the first Lancet Editorial of 2021, we noted: “Countries might justifiably start to look inward to repair the damage after COVID-19. But equitable access, whether to a vaccine, food, or finance, will require global collaboration.” This requirement has not been met. Science has provided the tools and evidence to control the COVID-19 pandemic, but the response has been shaped by political factors and a lack of cooperation, often to the detriment of health.

For all its peaks and troughs, 2021 should be heralded as the year of extraordinary COVID-19 science. 2021 began with several new vaccines showing efficacy in randomised trials. There are now 26 COVID-19 vaccines authorised by at least one national regulatory agency and another 200 candidates are in development. Novel treatments have provided further options to prevent death and disability. These achievements allowed for a new sense of hope that should have been the basis for an equitable global response, carried out with the urgency and seriousness that a devastating pandemic demands.

Massive vaccine roll-out programmes have also taken place with remarkably high participation in some countries, including Portugal (88%), Chile (86%), Cuba (83%), and Singapore (83%). Yet vaccination rates are notably lower in other countries that had early access to a COVID-19 vaccine—eg, Russia has reached only about 48% of its population as of December, 2021. Of all Americans who are eligible, only 61% are fully vaccinated. Although in vastly different contexts, those who are unvaccinated in Russia and the USA cite the same reasons: a mistrust of government, distrust of data, and few consequences for not being vaccinated.

The USA provides a potent demonstration of the structural barriers and stymied progress in COVID-19 that can originate from political obstacles to health. Socioeconomic disadvantage is a substantial contributor to vaccine hesitancy in low-income communities. Compliance with public health interventions, such as indoor masking, are often fomented by political ideologies. Lawsuits filed in federal appeal courts by Republican political action groups have thwarted vaccine mandate legislation for health-care workers and federal employees that would go into effect in 2022. A sizeable proportion of unvaccinated-by-choice Americans remain so even though they are eligible to receive a booster. Without incentives to reduce hesitancy, durable mandates for masking, and near complete vaccination, optimism dims for curtailing the next potential COVID-19 wave.

Political failures to cooperate and find solutions at the global level have shaped the pandemic too. Leaders of high-income countries have spoken of the importance of equitable access to COVID-19 vaccination, and pledged to donate doses, but have consistently been unable to deliver. Vaccine manufacturing continues to be hindered by a lack of agreement on relaxing intellectual property rules to increase and diversify capacity. The enormity of the situation has not been matched by the response. Leaders have been unable to realise that the status quo should not apply in a pandemic. As of this month, 75% of the population in high-income countries have received at least one dose of a COVID-19 vaccine compared with 46% in lower-middle-income countries, and just 7% in low-income countries. The emergence of new variants such as omicron jeopardises all.

Politically driven decisions are undermining health security. The most recent Global Health Security Index shows that risks to political stability and security have increased in nearly all countries, and those with the fewest resources have the highest risk. There is greater risk of social unrest. Most countries score low on accountability of public officials and human rights. All countries remain underprepared for the next pandemic and countries should be more transparent about their capacities and risk factors for better global preparation.

The emergence of omicron threatens new setbacks and further compounding of the harms of the pandemic. Science will no doubt continue to provide the means to respond. But doing so effectively and equitably will require greater recognition of the political determinants of health and action based on a robust global multilateral system and strong individual national leadership—which too often has been, and continues to be, lacking.

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

The Lancet
Dec 18, 2021 Volume 398 Number 10318 p2207-2306
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair P S Munro, et al. on behalf of the COV-BOOST study group
Open Access
Interpretation
All study vaccines boosted antibody and neutralising responses after ChAd/ChAd initial course and all except one after BNT/BNT, with no safety concerns. Substantial differences in humoral and cellular responses, and vaccine availability will influence policy choices for booster vaccination.

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial

The Lancet
Dec 18, 2021 Volume 398 Number 10318 p2207-2306
https://www.thelancet.com/journals/lancet/issue/current

 

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
Rajeka Lazarus, et al. and the ComfluCOV Trial Group
Open Access
Interpretation
Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine raises no safety concerns and preserves antibody responses to both vaccines. Concomitant vaccination with both COVID-19 and influenza vaccines over the next immunisation season should reduce the burden on health-care services for vaccine delivery, allowing for timely vaccine administration and protection from COVID-19 and influenza for those in need.

The emergence, genomic diversity and global spread of SARS-CoV-2

Nature
Volume 600 Issue 7889, 16 December 2021
https://www.nature.com/nature/volumes/600/issues/7889

 

Review Article | 08 December 2021
The emergence, genomic diversity and global spread of SARS-CoV-2
The potential origins and global spread of SARS-CoV-2, the emergence of SARS-CoV-2 variants of concern and the importance of genomic surveillance for the control of the COVID-19 pandemic are discussed.
Juan Li, Shengjie Lai, Weifeng Shi

Mapping the human genetic architecture of COVID-19

Nature
Volume 600 Issue 7889, 16 December 2021
https://www.nature.com/nature/volumes/600/issues/7889

 

Article | 08 July 2021 | Open Access
Mapping the human genetic architecture of COVID-19
A global network of researchers was formed to investigate the role of human genetics in SARS-CoV-2 infection and COVID-19 severity; this paper reports 13 genome-wide significant loci and potentially actionable mechanisms in response to infection.
Mari E. K. Niemi, Juha Karjalainen, Chloe Donohue

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination

Nature
Volume 600 Issue 7889, 16 December 2021
https://www.nature.com/nature/volumes/600/issues/7889

 

Article | 07 October 2021 | Open Access
Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
Individual memory antibodies selected over time by natural infection with SARS-CoV-2 have greater potency and breadth than antibodies elicited by vaccination, whereas the overall neutralizing potency of plasma is greater following vaccination.
Alice Cho, Frauke Muecksch, Michel C. Nussenzweig

Technologies to advance COVID-19 vaccine equity

Nature Biotechnology
Volume 39 Issue 12, December 2021
https://www.nature.com/nbt/volumes/39/issues/12

 

Editorial | 06 December 2021
Technologies to advance COVID-19 vaccine equity
Poor countries need vaccine formats with low barriers to manufacture, distribution and administration.
…The massive global effort over the past two years to develop, make, and administer vaccines against a novel, fast-spreading pathogen is unprecedented in the history of vaccines. The results are still unfolding and will have much to teach us about both the immunology of viral infection and the strengths and weaknesses of emerging COVID-19 vaccine technologies. With international cooperation and open data sharing, they may shed light on some of the most intractable problems in vaccinology: how best to make mucosal vaccines, how to induce robust immunity in the immunocompromised or aged people with immunosenescence, how best to increase the longevity of protection, and how to elicit broadly neutralizing antibodies against diverse viral lineages or a rapidly mutating virus.

The knowledge gained could lead to more-effective COVID-19 vaccines. Current vaccines greatly diminish the risks of infection, transmission, serious illness, and death but do not entirely prevent them, with immunocompromised and elderly people the most vulnerable. Efficacy wanes in a matter of months (in the age cohorts for which data are available — 16 and up). Improvements that can be envisaged include intranasal or oral vaccines for stronger mucosal immunity to reduce infection and transmission, and pan-sarbecovirus vaccines to protect against all SARS coronavirus strains.

No single vaccine will be best for every country and every pandemic condition. But we need to ensure that all people, including those in poor, rural, or remote communities, have access to highly effective and safe COVID-19 vaccines. Vaccine technologies that are validated for COVID-19 may also aid the development of vaccines for other infectious diseases, such as tuberculosis, pandemic influenza, malaria, and respiratory syncytial virus infection, and strengthen our preparedness to fight future pathogens.

Combination therapy patents: a new front in evergreening

Nature Biotechnology
Volume 39 Issue 12, December 2021
https://www.nature.com/nbt/volumes/39/issues/12

 

Patents | 08 December 2021
Combination therapy patents: a new front in evergreening
As pharmaceutical companies seek patent protection for combinations of cancer therapeutics, it is worthwhile to assess what constitutes an ‘unexpected result’ for the purpose of an appropriate patent and whether randomized, controlled trials of drug combinations have the ability to generate them.
Garth W. Strohbehn, Alec J. Kacew, Mark J. Ratain

Understanding resistance to medical AI

Nature Human Behaviour
Volume 5 Issue 12, December 2021
https://www.nature.com/nathumbehav/volumes/5/issues/12

 

Understanding resistance to medical AI
Previous research has shown that patients are reluctant to use medical artificial intelligence (AI). Cadario et al. find that this reluctance is due to people perceiving algorithms as a ‘black box’, coupled with an illusory sense of understanding medical decisions made by humans. Brief interventions that target subjective understanding of medical AI increase people’s willingness to use it…

Aspiring to greater intellectual humility in science

Nature Human Behaviour
Volume 5 Issue 12, December 2021
https://www.nature.com/nathumbehav/volumes/5/issues/12

 

Perspective | 28 October 2021
Aspiring to greater intellectual humility in science
Although intellectual humility is a prerequisite for credible science, it is rarely practised. Hoekstra and Vazire make recommendations on how to increase intellectual humility in research articles and highlight the crucial role of peer reviewers in promoting intellectually humble manuscripts.
Rink Hoekstra, Simine Vazire

Prepare developed democracies for long-run economic slowdowns

Nature Human Behaviour
Volume 5 Issue 12, December 2021
https://www.nature.com/nathumbehav/volumes/5/issues/12

 

Perspective | 18 November 2021
Prepare developed democracies for long-run economic slowdowns
The coming years are likely to see slowing economic growth, which has significant consequences for developed democracies. This Perspective by Burgess et al. considers the implications of slowed growth and proposes a guided civic revival approach to addressing challenges.
Matthew G. Burgess, Amanda R. Carrico, Steve Vanderheiden

Understanding, explaining, and utilizing medical artificial intelligence

Nature Human Behaviour
Volume 5 Issue 12, December 2021
https://www.nature.com/nathumbehav/volumes/5/issues/12

 

Article | 28 June 2021
Understanding, explaining, and utilizing medical artificial intelligence
Cadario et al. identify potential reasons underlying the resistance to use medical artificial intelligence and test interventions to overcome this resistance.
Romain Cadario, Chiara Longoni, Carey K. Morewedge

No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020

Nature Medicine
Volume 27 Issue 12, December 2021
https://www.nature.com/nm/volumes/27/issues/12

 

Article | 27 October 2021 | Open Access
No causal effect of school closures in Japan on the spread of COVID-19 in spring 2020
School closures in municipalities in Japan at the start of the COVID-19 pandemic showed no significant reduction in cases compared with case counts in municipalities with open schools, questioning the utility of school closures in mitigating community spread of severe acute respiratory syndrome coronavirus 2.
Kentaro Fukumoto, Charles T. McClean, Kuninori Nakagawa

The impact of school opening model on SARS-CoV-2 community incidence and mortality

Nature Medicine
Volume 27 Issue 12, December 2021
https://www.nature.com/nm/volumes/27/issues/12

 

Article | 27 October 2021
The impact of school opening model on SARS-CoV-2 community incidence and mortality
Results from a nationwide cohort study in the United States indicates that schools can reopen for in-person learning without substantially increasing community case rates of SARS-CoV-2.
Zeynep Ertem, Elissa M. Schechter-Perkins, Richard E. Nelson

Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Nature Medicine
Volume 27 Issue 12, December 2021
https://www.nature.com/nm/volumes/27/issues/12

 

Article | 14 October 2021 | Open Access
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
A large, community-based study in the United Kingdom indicates that the effectiveness of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infections with symptoms or high viral burden is reduced with the Delta variant compared to the Alpha variant.
Koen B. Pouwels, Emma Pritchard, A. Sarah Walker

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Nature Medicine
Volume 27 Issue 12, December 2021
https://www.nature.com/nm/volumes/27/issues/12

 

Article | 02 November 2021
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
mRNA COVID-19 vaccines are highly effective at preventing severe outcomes and death caused by the SARS-CoV-2 Delta variant (B.1.617.2) in Qatar despite substantially lower effectiveness at blocking infection.
Patrick Tang, Mohammad R. Hasan, Laith J. Abu-Raddad

Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 18 Dec 2021)

 

Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study
Mie Agermose Gram, Jens Nielsen, Astrid Blicher Schelde, Katrine Finderup Nielsen, Ida Rask Moustsen-Helms, Anne Katrine Bjørkholt Sørensen, Palle Valentiner-Branth, Hanne-Dorthe Emborg
Research Article | published 17 Dec 2021 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003874

Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center

PLoS One
http://www.plosone.org/
[Accessed 18 Dec 2021]

 

Research Article
Oncologists’ reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center
Jeremiah Stout, Cambray Smith, Jan Buckner, Alex A. Adjei, Mark Wentworth, Jon C. Tilburt, Zubin Master
Research Article | published 17 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0261478

Factors of parental COVID-19 vaccine hesitancy: A cross sectional study in Japan

PLoS One
http://www.plosone.org/
[Accessed 18 Dec 2021]

 

Factors of parental COVID-19 vaccine hesitancy: A cross sectional study in Japan
Sayaka Horiuchi, Haruka Sakamoto, Sarah K. Abe, Ryoji Shinohara, Megumi Kushima, Sanae Otawa, Hideki Yui, Yuka Akiyama, Tadao Ooka, Reiji Kojima, Hiroshi Yokomichi, Kunio Miyake, Takashi Mizutani, Zentaro Yamagata
Research Article | published 17 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0261121

A randomized controlled trial to evaluate the effect of influenza vaccination and probiotic supplementation on immune response and incidence of influenza-like illness in an elderly population in Indonesia

PLoS One
http://www.plosone.org/
[Accessed 18 Dec 2021]

 

A randomized controlled trial to evaluate the effect of influenza vaccination and probiotic supplementation on immune response and incidence of influenza-like illness in an elderly population in Indonesia
Sukamto Koesnoe, Nuning Masjkuri, Asri Adisasmita, Samsuridjal Djauzi, Cissy Kartasasmita, Julitasari Sundoro, Mardiati Nadjib, Mondastri Korib, Alisa Nurul Muthia, Virly Nanda Muzellina, Ummu Habibah, Saskia Aziza Nursyirwan, Kristoforus Hendra Djaya, Novilia Sjafri Bachtiar, Rini Mulia Sari
Research Article | published 16 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0250234

Knowledge and awareness of human papillomavirus infection and human papillomavirus vaccine among Kazakhstani women attending gynecological clinics

PLoS One
http://www.plosone.org/
[Accessed 18 Dec 2021]

 

Knowledge and awareness of human papillomavirus infection and human papillomavirus vaccine among Kazakhstani women attending gynecological clinics
Torgyn Issa, Aisha Babi, Alpamys Issanov, Ainur Akilzhanova, Kadisha Nurgaliyeva, Zauresh Abugalieva, Azliyati Azizan, Saleem A. Khan, Chee Kai Chan, Raushan Alibekova, Gulzhanat Aimagambetova
Research Article | published 13 Dec 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0261203

Religious identity cues increase vaccination intentions and trust in medical experts among American Christians

PNAS – Proceedings of the National Academy of Sciences of the United States
December 07, 2021; vol. 118 no. 49
https://www.pnas.org/content/118/49

 

Brief Report
Open Access
Religious identity cues increase vaccination intentions and trust in medical experts among American Christians
James Chu, Sophia L. Pink, and Robb Willer
PNAS December 7, 2021 118 (49) e2106481118; https://doi.org/10.1073/pnas.2106481118

Persuading US White evangelicals to vaccinate for COVID-19: Testing message effectiveness in fall 2020 and spring 2021

PNAS – Proceedings of the National Academy of Sciences of the United States
December 07, 2021; vol. 118 no. 49
https://www.pnas.org/content/118/49

 

Persuading US White evangelicals to vaccinate for COVID-19: Testing message effectiveness in fall 2020 and spring 2021
Scott E. Bokemper, Alan S. Gerber, Saad B. Omer, and Gregory A. Huber
PNAS December 7, 2021 118 (49) e2114762118; https://doi.org/10.1073/pnas.2114762118

The role of trust in the likelihood of receiving a COVID-19 vaccine: Results from a national survey

Preventive Medicine
Volume 153 December 2021
https://www.sciencedirect.com/journal/preventive-medicine/vol/153/suppl/C

 

Research article Full text access
The role of trust in the likelihood of receiving a COVID-19 vaccine: Results from a national survey
Peter G. Szilagyi, Kyla Thomas, Megha D. Shah, Nathalie Vizueta, … Arie Kapteyn
Article 106727

Time and geographic variations in human papillomavirus vaccine uptake in Washington state

Preventive Medicine
Volume 153 December 2021
https://www.sciencedirect.com/journal/preventive-medicine/vol/153/suppl/C

 

Research article Full text access
Time and geographic variations in human papillomavirus vaccine uptake in Washington state
Nastaran Pourebrahim, Parth Shah, Trang VoPham, David R. Doody, … Margaret M. Madeleine
Article 106753

Looking ahead in the COVID-19 pandemic: emerging lessons learned for sexual and reproductive health services in low- and middle-income countries

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 18 Dec 2021]

 

Looking ahead in the COVID-19 pandemic: emerging lessons learned for sexual and reproductive health services in low- and middle-income countries
Authors: Aduragbemi Banke-Thomas and Sanni Yaya
Content type: Editorial
14 December 2021

COVID-19 impact on infant and adolescent vaccine supplies

Science
Volume 374| Issue 6574| 17 Dec 2021
https://www.science.org/toc/science/current

 

Policy Forum
COVID-19 impact on infant and adolescent vaccine supplies
BY Tania Cernuschi…Alejandro Cravioto
16 Dec 2021: 1438-1441
Vaccine production is quadrupling rapidly, creating supply chain challenges
Immunization prevents 4 to 5 million deaths annually, primarily among children, but each year 20 million infants do not receive a full course of the most essential basic vaccines. COVID-19 has underscored the importance of vaccines to public health, but immunization coverage dropped in 2020 as a result of the pandemic, leaving even more infants un- or underimmunized (1). The push to manufacture COVID-19 vaccines has raised concerns that supplies of other essential vaccines may be compromised, which could erode the gains achieved by immunization and delay access for underserved populations. Drawing on data assembled by the World Health Organization (WHO) and on the advice of technical experts (see supplementary materials), we describe how COVID-19 is affecting the global supply of key infant and adolescent vaccines (see the table). We assess the risks to those essential vaccines, identify mitigations, and explore how emerging innovations can help improve market health…

Vaccines 2020: The era of the digital vaccine is here

Science Translational Medicine
Volume 13| Issue 624| 15 Dec 2021
https://www.science.org/toc/stm/current

 

Viewpoint
Vaccines 2020: The era of the digital vaccine is here
BY Mariagrazia Pizza, Simone Pecetta, Rino Rappuoli
15 Dec 2021
The SARS-CoV-2 pandemic has generated a renaissance in vaccinology, with COVID-19 mRNA vaccines delivering a “digital code” of the viral antigen with no need to purify proteins or inactivate pathogens.

100 years of the Bacillus Calmette-Guérin vaccine

Vaccine
Volume 39, Issue 50, Pages 7221-7356 (8 December 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/50

 

100 Years of the Bacillus Calmette-Guérin Vaccine
Editorial Full text access
100 years of the Bacillus Calmette-Guérin vaccine
Paulo J.G. Bettencourt, Simone A. Joosten, Cecilia S. Lindestam Arlehamn, Marcel A. Behr, … Olivier Neyrolles
Pages 7221-7222